114977-28-5

Basic information

• Product Name: 114977-28-5
• Synonyms: Benzenepropanoicacid, b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxy-,12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-ylester, [2aR-[2aa,4b,4ab,6b,9a(aR*,bS*),11a,12a,12aa,12ba]]-;Docetaxel Winthrop;Docetaxol;Docetaxolum;HSDB 6965;RP 56976;Taxotere
• CAS NO: 114977-28-5
• Molecular Formula: C₄₃H₅₃NO₁₄
• Molecular Weight: 807.88 .
• Mol File: 114977-28-5.mol
• Article Data: 62

Chemical Properties

• Melting Point: 232℃
• Boiling Point: 900.5 °C at 760 mmHg
• Flash Point: 498.4 °C
• Appearance: Off-white Cryst
• Density: 1.37 g/cm³
• Refractive Index: 1.618
• CAS DataBase Reference: 114977-28-5(CAS DataBase Reference)
• NIST Chemistry Reference: 114977-28-5(114977-28-5)
• EPA Substance Registry System: 114977-28-5(114977-28-5)

Safety Data

• Hazardous Substances Data: 114977-28-5(Hazardous Substances Data)

Usage

General Description

The chemical with the CAS number 114977-28-5 is a synthetic organic compound with a molecular formula that has not been disclosed. This chemical is known to be used in the production of pharmaceuticals, agrochemicals, and other specialty chemical products. It is categorized as a potential hazardous substance and is subject to strict regulations regarding its handling, storage, and transportation. Due to its proprietary nature, specific information about its properties and uses is not publicly available. However, it is important to handle this chemical with care and to follow all recommended safety protocols when working with it.

InChI:InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41-,42-,43+/m0/s1

Upstream product

• 32981-86-5 10-deacetylbaccatin III 
• 196404-55-4 acide (4S,5R)-N-(tert-butoxycarbonyl)-2-(4-O-methoxyphenyl)-4-phenyl-5-oxazolidine carboxylique 
• 151509-27-2 2'-acetyldocetaxel 
• 95603-44-4 7,10-di-(2,2,2-trichloroethyloxycarbonyl)-10-deacetylbaccatin III 
• 1021489-55-3 SPT₁₁₄₁ M₆ 
• 24424-99-5 di-tert-butyl dicarbonate 
• 159262-93-8 10-deacetylbaccatin III-13-O-[(4S,5R)-4-phenyl-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidine-5-carboxylate] 
• 148408-66-6 N-tert-butoxycarbonyl-10-deacetyl-N-debenzoyl-taxol trihydrate 
• 162785-05-9 C₄₉H₆₇NO₁₄Si 
• 155396-73-9 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1,13α-dihydroxy-9-oxo-11-taxen-13α-yl (2R,3S)-3-(tert-butoxycarbonylamino)-3-phenyl-2-(benzyloxy)-propionate 
• 670254-71-4 (2*,4S,5R)-methyl N-tert-butoxycarbonyl-2-(4'-methoxy)phenyl-4-phenyl-1,3-oxazolidine-5-methionate 
• 195141-96-9 2'-(tert-butyldimethylsilyl)-7,10-di(triethylsilyl)docetaxel 
• 125354-16-7 10-acetyldocetaxel 
• 1053738-36-5 C₅₆H₆₁Cl₆NO₁₆ 

Downstream Products

• 170171-53-6 2'-O-(2,2,2-trichloroethoxycarbonyl)docetaxel 
• 262598-45-8 2',10-bis-O-(2,2,2-trichloroethoxycarbonyl)docetaxel 
• 1068633-26-0 docetaxel/mono propylene glycol clathrate 
• 153381-68-1 7-epi-docetaxel 
• 1257204-10-6 10-deacetyl-N-debenzoyl-N-(tert-butyloxycarbonyl)-2',7-bis[(N-piperidin-1-yl)succinamidoyl]taxol 
• 1221403-99-1 2'-O-methacryloylglycylphenylalanylleucylglycyl-docetaxel 
• 1385028-85-2 C₄₃H₅₅NO₁₅ 
• 1308398-49-3 docetaxel-2'-glycinate methanesulfonate 
• 1040916-32-2 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-2-((((benzyloxy)carbonyl)glycyl)oxy)-3-((tert-butoxycarbonyl)amino)-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate 
• 1308398-37-9 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-2-((6-(((benzyloxy)carbonyl)amino)hexanoyl)oxy)-3-((tert-butoxycarbonyl)amino)-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate 
• 1308398-38-0 2'-(6-amino-caproyl)docetaxel methanesulfonate 
• 1308398-48-2 docetaxel-2'-glycine bsmoc 

Relevant articles and documents

Semisynthesis method for docetaxel

The invention relates to a semisynthesis method for docetaxel. The semisynthesis method comprises the following steps: protecting hydroxyl groups on 7-carbon and 10-carbon on 10-DAB III by using chloroformic acid-2,2,2-trichloroethyl ester so as to obtain an intermediate I, performing a condensation reaction on the intermediate I and a five-membered ring side chain so as to obtain an intermediateII, performing ring opening on the intermediate II under the action of hydrochloric acid to remove a protecting group on the five-membered ring side chain so as to obtain an intermediate III, and removing a Troc protecting group from the intermediate III under an acidic condition so as to obtain the docetaxel. The semisynthesis method provided by the invention has the advantages of simple processroute, mild reaction conditions, fewer impurities generated in the reaction process, higher yield and stable properties of obtained intermediates, and applicability to industrial large-scale production.

Method for purifying docetaxel

The invention discloses a method for purifying docetaxel. A docetaxel solid precipitates from a dichloromethane and toluene mixed solution. The purifying method has the advantages of great reduction of the single content of every impurity in docetaxel, introduction of few impurities, improvement of the purity of the product, and high yield, and is very suitable for industrial large-scale production, and the obtained product meets preparation demands, and can be directly used to prepare a docetaxel injection.

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs

Ephrin A2 targeted immunoliposomes incorporating pH-sensitive taxane prodrugs were developed for sustained delivery of active drug to solid tumors. Here we describe the systematic formulation development and characterization of these immunoliposomes. We s